Course

New Targets, New Therapies: What Does the Future Hold in the Treatment Of RA?

0 out of 5 steps completed0%
0 Lessons

Course Summary

This issue of Rheumatology Nurse Practice will explore the growing base of knowledge regarding the pathophysiology of RA and how new agents being developed are targeting new pathways in new ways. It will also examine the growing role of biosimilars as they begin to be introduced more regularly into clinical care.

Target Audience

This activity has been designed to meet the educational needs of nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.

Learning Objectives

After participating in the activity, learners should be better able to:

  • List the genetic and environmental drivers of rheumatoid arthritis (RA) that have recently been studied by clinical researchers
  • Identify the therapeutic targets of agents currently under investigation for the treatment of RA
  • Discuss reasons why the Janus kinase pathway is thought to be of particular promise as a therapeutic target in patients with RA
  • Analyze the strategies you use to discuss the diagnosis of RA with new patients and identify opportunities to better fine-tune those conversations

Accreditation Statement

Rheumatology Nurses Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).

Rheumatology Nurses Society designates this educational activity for 3.3 total contact hours and 2.5 CNE pharmacotherapeutic contact hours.

Faculty Disclosures

According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Iris Zink, MSN, NP, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: AbbVie, Bristol-Myers Squibb, Horizon, Crescendo/SB; Pfizer/C.

Jacqueline Fritz, RN, MSN, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Horizon, Momentum, AbbVie, Sanofi Genzyme/SB.

Carrie Beach, BSN, RN-BC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Celgene, Merck, Sanofi/A.

Cathy Patty-Resk, MSN, RN-BC, CPNP-PC, has disclosed the following relevant financial relationships specific to the subject matter of the content included in this educational activity: Celgene/A.

Copyright Statement

© 2019. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).